226 related articles for article (PubMed ID: 29028155)
1. A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease.
Brinkmalm G; Sjödin S; Simonsen AH; Hasselbalch SG; Zetterberg H; Brinkmalm A; Blennow K
Proteomics Clin Appl; 2018 Jan; 12(1):. PubMed ID: 29028155
[TBL] [Abstract][Full Text] [Related]
2. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.
Duits FH; Brinkmalm G; Teunissen CE; Brinkmalm A; Scheltens P; Van der Flier WM; Zetterberg H; Blennow K
Alzheimers Res Ther; 2018 Jan; 10(1):5. PubMed ID: 29370833
[TBL] [Abstract][Full Text] [Related]
3. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases.
Yin GN; Lee HW; Cho JY; Suk K
Brain Res; 2009 Apr; 1265():158-70. PubMed ID: 19368810
[TBL] [Abstract][Full Text] [Related]
4. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
Collins MA; An J; Hood BL; Conrads TP; Bowser RP
J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
[TBL] [Abstract][Full Text] [Related]
5. High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.
Hendrickson RC; Lee AY; Song Q; Liaw A; Wiener M; Paweletz CP; Seeburger JL; Li J; Meng F; Deyanova EG; Mazur MT; Settlage RE; Zhao X; Southwick K; Du Y; Holder D; Sachs JR; Laterza OF; Dallob A; Chappell DL; Snyder K; Modur V; King E; Joachim C; Bondarenko AY; Shearman M; Soper KA; Smith AD; Potter WZ; Koblan KS; Sachs AB; Yates NA
PLoS One; 2015; 10(8):e0135365. PubMed ID: 26270474
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease.
Sathe G; Na CH; Renuse S; Madugundu AK; Albert M; Moghekar A; Pandey A
Proteomics Clin Appl; 2019 Jul; 13(4):e1800105. PubMed ID: 30578620
[TBL] [Abstract][Full Text] [Related]
7. Mass Spectrometry-Based Quantification of Tau in Human Cerebrospinal Fluid Using a Complementary Tryptic Peptide Standard.
Zhou M; Duong DM; Johnson ECB; Dai J; Lah JJ; Levey AI; Seyfried NT
J Proteome Res; 2019 Jun; 18(6):2422-2432. PubMed ID: 30983353
[TBL] [Abstract][Full Text] [Related]
8. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
Spellman DS; Wildsmith KR; Honigberg LA; Tuefferd M; Baker D; Raghavan N; Nairn AC; Croteau P; Schirm M; Allard R; Lamontagne J; Chelsky D; Hoffmann S; Potter WZ; ;
Proteomics Clin Appl; 2015 Aug; 9(7-8):715-31. PubMed ID: 25676562
[TBL] [Abstract][Full Text] [Related]
10. Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry.
Camporesi E; Nilsson J; Vrillon A; Cognat E; Hourregue C; Zetterberg H; Blennow K; Becker B; Brinkmalm A; Paquet C; Brinkmalm G
EBioMedicine; 2022 Jan; 75():103793. PubMed ID: 34990894
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
[TBL] [Abstract][Full Text] [Related]
12. Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.
Jahn H; Wittke S; Zürbig P; Raedler TJ; Arlt S; Kellmann M; Mullen W; Eichenlaub M; Mischak H; Wiedemann K
PLoS One; 2011; 6(10):e26540. PubMed ID: 22046305
[TBL] [Abstract][Full Text] [Related]
13. Combined tissue and fluid proteomics with Tandem Mass Tags to identify low-abundance protein biomarkers of disease in peripheral body fluid: An Alzheimer's Disease case study.
Russell CL; Heslegrave A; Mitra V; Zetterberg H; Pocock JM; Ward MA; Pike I
Rapid Commun Mass Spectrom; 2017 Jan; 31(2):153-159. PubMed ID: 27813239
[TBL] [Abstract][Full Text] [Related]
14. An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.
Hölttä M; Minthon L; Hansson O; Holmén-Larsson J; Pike I; Ward M; Kuhn K; Rüetschi U; Zetterberg H; Blennow K; Gobom J
J Proteome Res; 2015 Feb; 14(2):654-63. PubMed ID: 25490617
[TBL] [Abstract][Full Text] [Related]
15. Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.
Lleó A; Núñez-Llaves R; Alcolea D; Chiva C; Balateu-Paños D; Colom-Cadena M; Gomez-Giro G; Muñoz L; Querol-Vilaseca M; Pegueroles J; Rami L; Lladó A; Molinuevo JL; Tainta M; Clarimón J; Spires-Jones T; Blesa R; Fortea J; Martínez-Lage P; Sánchez-Valle R; Sabidó E; Bayés À; Belbin O
Mol Cell Proteomics; 2019 Mar; 18(3):546-560. PubMed ID: 30606734
[TBL] [Abstract][Full Text] [Related]
16. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls.
Pannee J; Portelius E; Oppermann M; Atkins A; Hornshaw M; Zegers I; Höjrup P; Minthon L; Hansson O; Zetterberg H; Blennow K; Gobom J
J Alzheimers Dis; 2013; 33(4):1021-32. PubMed ID: 23076076
[TBL] [Abstract][Full Text] [Related]
17. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease.
Öhrfelt A; Brinkmalm A; Dumurgier J; Brinkmalm G; Hansson O; Zetterberg H; Bouaziz-Amar E; Hugon J; Paquet C; Blennow K
Alzheimers Res Ther; 2016 Oct; 8(1):41. PubMed ID: 27716408
[TBL] [Abstract][Full Text] [Related]
18. SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer's disease.
Park SA; Jung JM; Park JS; Lee JH; Park B; Kim HJ; Park JH; Chae WS; Jeong JH; Choi SH; Baek JH
Sci Rep; 2020 May; 10(1):7423. PubMed ID: 32366888
[TBL] [Abstract][Full Text] [Related]
19. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects.
Castaño EM; Roher AE; Esh CL; Kokjohn TA; Beach T
Neurol Res; 2006 Mar; 28(2):155-63. PubMed ID: 16551433
[TBL] [Abstract][Full Text] [Related]
20. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
